CoChat

Effects of Additive Therapy with Spironolactone on Proteinuria in Diabetic Patients Already on ACE Inhibitor or ARB Therapy: Results of a Randomized, Placebo-Controlled, Double-Blind, Crossover Trial

Saklayen, Mohammad G., Gyebi, Leonard K., Tasosa, Joseph, Yap, Jayson · 2008 · Journal of Investigative Medicine
Cited by 65

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Introduction: Aldosterone seems to have deleterious effects on the kidneys. Many animal studies and a few clinical trials have shown that suppression of aldosteroneby aldosterone receptor blockers ameliorates these effects. Method: In a double-blind crossover study, patients with diabetic nephropathy who were already receiving either angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) were given spironolactone or matching placebo with 1 month of washout in between. Blood pressure (BP), serum creatinine, serum potassium, and spot urine protein/creatinine were measured at the beginning and end of each study period. Results: Mean systolic BP on spironolactone went down from 153.64 (±25.95) at the beginning to 141.60 (±16.54) at the end of study ( P = 0.01). Diastolic BP during spironolactone therapy did not change significantly. The urine protein/creatinine increased from 1.24 (±1.13) to 1.57 (±2.13) on placebo ( P = 0.35) and decreased from 1.80 (±1.78) to 0.79 (±0.99) during spironolactone therapy ( P = 0.004). In other words proteinuria increased by 24% during the placebo treatment period but decreased by half (57%) during the active treatment. Serum potassium increased from 4.29 (±0.47) to 4.64 (±0.55) during spironolactone therapy ( P = 0.002), no significant change with placebo. Whereas serum creatinine did not change on placebo, it increased from 1.35 (±0.54) to 1.56 (±0.62) on spironolactone ( P = 0.006). Glomerular filtration rate decreased from 61.91 (±23.4) to 53.94 (±23.58) on spironolactone ( P = 0.0001) but not on placebo. Conclusions: Addition of a modest dose of spironolactone to a regimen of ACEI or ARB in patients with diabetic proteinuria causes further reduction in proteinuria and also lowers the systolic BP. As with ACEI or ARB, spironolactone modestly reduces the glomerular filtration rate and raises serum potassium.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2310/jim.0b013e31816d78e9

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 65

Metadata

Authors
Saklayen, M. G., Gyebi, L. K., Tasosa, J., & Yap, J.
Venue
Journal of Investigative Medicine
Published
2008-04
Volume
56
Issue
4
Pages
714-719
ISSN
  • 1081-5589 (ISSN-L)
  • 1708-8267
OpenAlex
W281788183
Cited by
65
References
2
FWCI
1.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Additive Therapy with Spironolactone on Proteinuria in Diabetic Patients Already on ACE Inhibitor or ARB Therapy: Results of a Randomized, Placebo-Controlled, Double-Blind, Crossover Trial. https://app.cochat.ai/papers/10.2310/jim.0b013e31816d78e9
The paper
Saklayen, M. G., Gyebi, L. K., Tasosa, J., & Yap, J. (2008). Effects of Additive Therapy with Spironolactone on Proteinuria in Diabetic Patients Already on ACE Inhibitor or ARB Therapy: Results of a Randomized, Placebo-Controlled, Double-Blind, Crossover Trial. Journal of Investigative Medicine. https://doi.org/10.2310/jim.0b013e31816d78e9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.